Drug-induced gynecomastia

Pharmacotherapy

Volumn 32, Issue 12, 2012, Pages 1123-1140

  Bowman, John D ^a   Kim, Hyunah ^b   Bustamante, Juan J ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b Ajou University   (South Korea)

Author keywords

Adverse effect; Drug effects; Endocrinology; Estrogen; Gynecomastia; Hyperprolactinemia; Hypogonadism; Sex hormone; Testosterone

Indexed keywords

BICALUTAMIDE; CLONIDINE; DIDANOSINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DUTASTERIDE; EFAVIRENZ; ENTECAVIR; EPLERENONE; ETHAMBUTOL; FINASTERIDE; FLUTAMIDE; INDINAVIR; ISONIAZID; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR; METRONIDAZOLE; NELFINAVIR; NILUTAMIDE; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SPIRONOLACTONE; STAVUDINE; UNINDEXED DRUG; VERAPAMIL; ZIDOVUDINE;

ANDROGEN DEPRIVATION THERAPY; COCCIDIOIDOMYCOSIS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GYNECOMASTIA; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPROLACTINEMIA; HYPERTENSION; MASTALGIA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUBERCULOSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANDROGEN ANTAGONISTS; ANDROGENS; ESTROGENS; GYNECOMASTIA; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84871599454     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1138     Document Type: Review

References (150)

1. Sasano H, Kimura M, Shizawa S, Kimura N, Nagura H. Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab 1996;81:3063-7 (Pubitemid 26323909)
2. Burgess HE, Shousha S. An immunohistochemical study of the long-term effects of androgen administration on femaleto- male transsexual breast: a comparison with normal female breast and male breast showing gynaecomastia. J Pathol 1993;170:37-43 (Pubitemid 23130582)
3. Barrett KE, Ganong WF. Ganong's review of medical physiology, 23rd ed. New York, NY: McGraw-Hill Medical, 2010:1 online resource (ix, 714 p.)
4. Mathur R, Braunstein GD. Gynecomastia: pathomechanisms and treatment strategies. Horm Res 1997;48:95-102 (Pubitemid 27371019)
5. Gikas P, Mokbel K. Management of gynaecomastia: an update. Int J Clin Pract 2007;61:1209-15 (Pubitemid 46934608)
6. Thompson DF, Carter Jr. Drug-induced gynecomastia. Pharmacotherapy 1993;13:37-45 (Pubitemid 23045282)
7. Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007;357:1229-37
8. Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977;87:398-403
9. Narula HS, Carlson HE. Gynecomastia. Endocrinol Metab Clin North Am 2007;36:497-519 (Pubitemid 46830749)
10. Andersen JA, Gram JB. Gynecomasty: histological aspects in a surgical material. Acta Pathol Microbiol Immunol Scand A 1982;90:185-90 (Pubitemid 12124289)
11. Gill S, Peston D, Vonderhaar BK, Shousha S. Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol 2001;54:956-60 (Pubitemid 34032892)
12. Carlson HE, Kane P, Lei ZM, Li X, Rao CV. Presence of luteinizing hormone/human chorionic gonadotropin receptors in male breast tissues. J Clin Endocrinol Metab 2004;89: 4119-23 (Pubitemid 39071521)
13. Bedognetti D, Rubagotti A, Zoppoli G, Boccardo F. Gynaecomastia: the anastrozole paradox. J Pediatr Endocrinol Metab 2010;23:205-6
14. Wibowo E, Schellhammer P, Wassersug RJ. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol 2011;185:17-23
15. McLeod DG, Iversen P. Gynecomastia in patients with prostate cancer: a review of treatment options. Urology 2000;56:713-20
16. Autorino R, Perdona S, D'Armiento M, et al. Gynecomastia in patients with prostate cancer: update on treatment options. Prostate Cancer Prostatic Dis 2006;9:109-14 (Pubitemid 43970958)
17. Flaig TW, Glode LM. Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother 2008;9:2829-41
18. Kim HS, Freedland SJ. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Support Palliat Care 2010;4:147-52
19. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003;8:474-87 (Pubitemid 37238876)
20. Wirth MP, See WA, McLeod DG, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004;172:1865-70 (Pubitemid 39363075)
21. Gillatt D. Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J Cancer Res Clin Oncol 2006;132(suppl 1):S17-26 (Pubitemid 46360130)
22. Feltquate D, Nordquist L, Eicher C, et al. Rapid androgen cycling as treatment for patients with prostate cancer. Clin Cancer Res 2006;12:7414-21 (Pubitemid 46095416)
23. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC data center. Eur Urol 1998;33:144-51
24. Wilt TJ, Macdonald R, Hagerty K, et al. 5-alpha-reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int 2010;106:1444-51
25. Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer during finasteride therapy. N Engl J Med 1996;335:823 (Pubitemid 26296550)
26. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS study group. Proscar long-term efficacy and safety study. Urology 1998;52:195-201; discussion 2
27. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24 (Pubitemid 36859473)
28. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202
29. Ferrando J, Grimalt R, Alsina M, Bulla F, Manasievska E. Unilateral gynecomastia induced by treatment with 1 mg of oral finasteride. Arch Dermatol 2002;138:543-4 (Pubitemid 34290044)
30. Ramot Y, Czarnowicki T, Zlotogorski A. Finasteride induced gynecomastia: case report and review of the literature. Int J Trichology 2009;1:27-9
31. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63:709-15 (Pubitemid 38479415)
32. Desgrandchamps F, Droupy S, Irani J, Saussine C, Comenducci A. Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. BJU Int 2006;98:83-8 (Pubitemid 43885511)
33. Pont A, Williams PL, Loose DS, et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 1982;97:370-2 (Pubitemid 12061586)
34. Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 1991;35:347-52
35. Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987;31:1874-8 (Pubitemid 18009552)
36. Satoh T, Tomikawa Y, Takanashi K, Itoh S, Yoshizawa I. Studies on the interactions between drugs and estrogen. III. Inhibitory effects of 29 drugs reported to induce gynecomastia on the glucuronidation of estradiol. Biol Pharm Bull 2004;27:1844-9 (Pubitemid 41701616)
37. Garg R, Vaibhav, Mehra S, Prasad R. Isoniazid induced gynaecomastia: a case report. Indian J Tuberc 2009;56: 51-4
38. Khanna P, Panjabi C, Maurya V, Shah A. Isoniazid associated, painful, bilateral gynaecomastia. Indian J Chest Dis Allied Sci 2003;45:277-9
39. Bayramicli OU, Ahishali E, Dabak R, Ak O, Dolapcioglu C. A case of gynecomastia due to entecavir. Turk J Gastroenterol 2010;21:313-6
40. Christeff N, Gharakhanian S, Thobie N, Rozenbaum W, Nunez EA. Evidence for changes in adrenal and testicular steroids during HIV infection. J Acquir Immune Defic Syndr 1992;5:841-6
41. Raffi F, Brisseau JM, Planchon B, Rémi JP, Barrier JH, Grolleau JY. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 1991;5:729-33
42. Caeiro JP, Visnegarwala F, Rodriguez-Barradas MC. Gynecomastia associated with indinavir therapy. Clin Infect Dis 1998;27:1539-40 (Pubitemid 29242442)
43. Schürmann D, Bergmann F, Ehrenstein T, Padberg J. Gynaecomastia in a male patient during protease inhibitor treatment for acute HIV disease. AIDS 1998;12:2232-3 (Pubitemid 28495282)
44. Peyriere H, Mauboussin JM, Rouanet I, et al. Report of gynecomastia in five male patients during antiretroviral therapy for HIV infection. AIDS 1999;13:2167-9 (Pubitemid 29509596)
45. Melbourne KM, Brown SL, Silverblatt FJ. Gynecomastia with stavudine treatment in an HIV-positive patient. Ann Pharmacother 1998;32:1108 (Pubitemid 28498475)
46. Manfredi R, Calza L, Chiodo F. Gynecomastia associated with highly active antiretroviral therapy. Ann Pharmacother 2001;35:438-9 (Pubitemid 32260211)
47. Strub C, Kaufmann GR, Flepp M, et al. Gynecomastia and potent antiretroviral therapy. AIDS 2004;18:1347-9 (Pubitemid 38822719)
48. Donovan B, Bodsworth NJ, Mulhall BP, Allen D. Gynaecomastia associated with saquinavir therapy. Int J STD AIDS 1999;10:49-50 (Pubitemid 29039160)
49. Manfredi R, Calza L, Chiodo F. Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones. J Acquir Immune Defic Syndr 2004;35:99-102 (Pubitemid 38044792)
50. Caso JA, Prieto JeM, Casas E, Sanz J. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz. AIDS 2001;15:1447-8 (Pubitemid 32662300)
51. Jover F, Cuadrado JM, Roig P, Rodriguez M, Andreu L, Merino J. Efavirenz-associated gynecomastia: report of five cases and review of the literature. Breast J 2004;10:244-6 (Pubitemid 38715743)
52. Qazi NA, Morlese JF, King DM, Ahmad RS, Gazzard BG, Nelson MR. Gynaecomastia without lipodystrophy in HIV-1- seropositive patients on efavirenz: an alternative hypothesis. AIDS 2002;16:506-7 (Pubitemid 34165393)
53. Mercié P, Viallard JF, Thiébaut R, et al. Efavirenz-associated breast hypertrophy in HIV-infection patients. AIDS 2001;15:126-9 (Pubitemid 32055791)
54. Evans DL, Pantanowitz L, Dezube BJ, Aboulafia DM. Breast enlargement in 13 men who were seropositive for human immunodeficiency virus. Clin Infect Dis 2002;35:1113-9 (Pubitemid 35239472)
55. Qazi NA, Morlese JF, King DM, Ahmad RS, Gazzard BG, Nelson MR. True gynaecomastia, another manifestation of immune reconstitution disease? Int J STD AIDS 2002;13:59-65
56. Mendhekar DN. Clonidine-induced gynecomastia and hyperprolactinemia in a 6-year-old child. J Clin Psychiatry 2005;66:1616-7
57. Barnes BJ, Howard PA. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Ann Pharmacother 2005;39:68-76 (Pubitemid 40052381)
58. Dimitriadis G, Papadopoulos V, Mimidis K. Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics. Hepatol Int 2011;5:738-9
59. Parthasarathy HK, Menard J, White WB, et al. A doubleblind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011;29:980-90
60. Cuculi F, Suter A, Erne P. Spironolactone-induced gynecomastia. CMAJ 2007;176:620
61. Cornes PG, Hole AC. Amlodipine gynaecomastia. Breast 2001;10:544-5 (Pubitemid 33150373)
62. Komine N, Takeda Y, Nakamata T. Amlodipine-induced gynecomastia in two patients on long-term hemodialysis therapy. Clin Exp Nephrol 2003;7:85-6 (Pubitemid 36460549)
63. Zochling J, Large G, Fassett R. Gynaecomastia and amlodipine. Med J Aust 1994;160:807
64. Otto C, Richter WO. Unilateral gynecomastia induced by treatment with diltiazem. Arch Intern Med 1994;154:351 (Pubitemid 24055893)
65. Tanner LA, Bosco LA. Gynecomastia associated with calcium channel blocker therapy. Arch Intern Med 1988;148: 379-80 (Pubitemid 18064814)
66. Boyd IW, for the Adverse Drug Reactions Advisory Committee. Gynaecomastia in association with calcium antagonists. Med J Aust 1994;161:328 (Pubitemid 24280609)
67. Nakamura Y, Yoshimoto K, Saima S. Gynaecomastia induced by angiotensin converting enzyme inhibitor. BMJ 1990; 300:541 (Pubitemid 20085555)
68. Jefferys DB. Painful gynaecomastia treated with tamoxifen. Br Med J 1979;1:1119-20 (Pubitemid 9153240)
69. Goh SY, Loh KC. Gynaecomastia and the herbal tonic "Dong Quai." Singapore Med J 2001;42:115-6 (Pubitemid 32294659)
70. Martinez J, Lewi JE. An unusual case of gynecomastia associated with soy product consumption. Endocr Pract 2008;14:415-8
71. Antonelli D, Luboshitzky R, Gelbendorf A. Amiodaroneinduced gynecomastia. N Engl J Med 1986;315:1553
72. Aerts J, Karmochkine M, Raguin G. Gynecomastia due to pravastatin [in French]. Presse Med 1999;28:787
73. Hammons KB, Edwards RF, Rice WY. Golf-inhibiting gynecomastia associated with atorvastatin therapy. Pharmacotherapy 2006;26:1165-8 (Pubitemid 44167824)
74. Oteri A, Catania MA, Travaglini R, et al. Gynecomastia possibly induced by rosuvastatin. Pharmacotherapy 2008; 28:549-51 (Pubitemid 351466467)
75. Picolos MK, Zeniou V, Michalis A. Rosuvastatin-induced gynaecomastia. Clin Endocrinol (Oxf) 2010;73:421-2
76. Gardette V, Vezzosi D, Maiza JC, Montastruc JL, Olivier P. Gynecomastia associated with fenofibrate. Ann Pharmacother 2007;41:508-10
77. Abe K, Mitsuka T, Kanamori S, Yamashita K, Yamaoka A. Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis. Mod Rheumatol 2007;17:511-3
78. Fukushi J, Nakashima Y, Iwamoto Y. Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis ameliorated by folate supplement. Rheumatol Int 2010;30:1371-2
79. Harris E, Mahendra P, McGarrigle HH, Linch DC, Chatterjee R. Gynaecomastia with hypergonadotrophic hypogonadism and Leydig cell insufficiency in recipients of high-dose chemotherapy or chemo-radiotherapy. Bone Marrow Transplant 2001;28:1141-4 (Pubitemid 34082970)
80. Aki FT, Tekin MI, Ozen H. Gynecomastia as a complication of chemotherapy for testicular germ cell tumors. Urology 1996;48:944-6 (Pubitemid 26427108)
81. Sherins RJ, Olweny CL, Ziegler JL. Gynecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkin's disease. N Engl J Med 1978;299:12-6 (Pubitemid 8387365)
82. Olweny CL, Katongole-Mbidde E, Kiire C, Lwanga SK, Magrath I, Ziegler JL. Childhood Hodgkin's disease in Uganda: a ten year experience. Cancer 1978;42:787-92 (Pubitemid 8406612)
83. Whitehead E, Shalet SM, Jones PH, Beardwell CG, Deakin DP. Gonadal function after combination chemotherapy for Hodgkin's disease in childhood. Arch Dis Child 1982;57: 287-91 (Pubitemid 12155434)
84. Gambacorti-Passerini C, Tornaghi L, Cavagnini F, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet 2003;361:1954-6 (Pubitemid 36694586)
85. Kim H, Chang HM, Ryu MH, et al. Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor. J Korean Med Sci 2005;20:512-5 (Pubitemid 40905533)
86. Caocci G, Atzeni S, Orru N, et al. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia 2008;22:2127-8
87. Ballardini P, Margutti G, Aliberti C, Manfredini R. Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma. Clin Drug Investig 2009;29:487-90
88. Garcia Rodriguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994;308:503-6
89. Stratakis CA, Batista D, Sabnis G, Brodie A. Prepubertal gynaecomastia caused by medication or the aromatase excess syndrome. Clin Endocrinol (Oxf) 2004;61:779-80 (Pubitemid 40006801)
90. Convens C, Verhelst J, Mahler C. Painful gynaecomastia during omeprazole therapy. Lancet 1991;338:1153
91. Lindquist M, Edwards IR. Endocrine adverse effects of omeprazole. BMJ 1992;305:451-2
92. Carvajal A, Macias D, Gutierrez A, et al. Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish pharmacovigilance system. Drug Saf 2007;30:527-31 (Pubitemid 46873077)
93. World Anti-Doping Agency. Prohibited List 2012. Available from www.wada-ama.org/en/Science-Medicine/Prohibited List. Accessed April 24, 2012
94. Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab 2010;95:1533-43
95. Finkelstein JS, McCully WF, MacLaughlin DT, Godine JE, Crowley WF Jr. The mortician's mystery. Gynecomastia and reversible hypogonadotropic hypogonadism in an embalmer. N Engl J Med 1988;318:961-5 (Pubitemid 18094990)
96. Gottswinter JM, Korth-Schü tz S, Ziegler R. Gynecomastia caused by estrogen containing hair lotion. J Endocrinol Invest 1984;7:383-6 (Pubitemid 14014314)
97. James-Todd T, Senie R, Terry MB. Racial/ethnic differences in hormonally-active hair product use: a plausible risk factor for health disparities. J Immigr Minor Health 2011;14: 506-11
98. Halpérin DS, Sizonenko PC. Prepubertal gynecomastia following topical inunction of estrogen containing ointment. Helv Paediatr Acta 1983;38:361-6 (Pubitemid 14227304)
99. Felner EI, White PC. Prepubertal gynecomastia: indirect exposure to estrogen cream. Pediatrics 2000;105:E55
100. Voelker R. Estrogen spray poses risks to children, pets through contact with treated skin. JAMA 2010;304:953
101. Jurewicz J, Hanke W. Exposure to phthalates: reproductive outcome and children health. A review of epidemiological studies. Int J Occup Med Environ Health 2011;24:115-41
102. Durmaz E, Ozmert EN, Erkekoglu P, et al. Plasma phthalate levels in pubertal gynecomastia. Pediatrics 2010;125: e122-9
103. Toorians AW, Bovee TF, De Rooy J, Stolker LA, Hoogenboom RL. Gynaecomastia linked to the intake of an herbal supplement fortified with diethylstilbestrol. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2010;27:917-25
104. Pishdad GR, Pishdad P, Pishdad R. Breast enlargement with prednisone treatment. Am J Med Sci 2011;342:425-6
105. Tooley PH, Lack C. Gynecomastia during treatment with amphetamine. Lancet 1949;1:650
106. Adler RA. Clinical review 33: clinically important effects of alcohol on endocrine function. J Clin Endocrinol Metab 1992;74:957-60
107. Noth RH, Walter RM. The effects of alcohol on the endocrine system. Med Clin North Am 1984;68:133-46 (Pubitemid 14179086)
108. Heufelder AE, Leinung MC, Northcutt RC. Holiday gynecomastia. Ann Intern Med 1992;116:877
109. Camiel MR, Alexander LL, Benninghoff DL. Drug addiction and gynecomastia. N Y State J Med 1967;67:2494-5
110. Lange WR, Ball JC, Pfeiffer MB, Snyder FR, Cone EJ. The Lexington addicts, 1971-1972: demographic characteristics, drug use patterns, and selected infectious disease experience. Int J Addict 1989;24:609-26 (Pubitemid 20072658)
111. Harmon JW, Aliapoulios MA. Marijuana-induced gynecomastia: clinical and laboratory experience. Surg Forum 1974;25:423-5
112. Cates W Jr, Pope JN. Gynecomastia and cannabis smoking. A nonassociation among US Army soldiers. Am J Surg 1977;134:613-5 (Pubitemid 8229979)
113. Sauer MA, Rifka SM, Hawks RL, Cutler GB Jr, Loriaux DL. Marijuana: interaction with the estrogen receptor. J Pharmacol Exp Ther 1983;224:404-7 (Pubitemid 13139098)
114. Allen RC, Wallace AM, Royce M. Marinol-induced gynecomastia: a case report. Am J Med 2007;120:e1 (Pubitemid 47454725)
115. de la Rosa RE, Hennessey JV. Hypogonadism and methadone: hypothalamic hypogonadism after long-term use of high-dose methadone. Endocr Pract 1996;2:4-7
116. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychoticinduced hyperprolactinemia. Pharmacotherapy 2009;29: 64-73
117. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005;80:1050-7 (Pubitemid 41099391)
118. Haddad PM, Hellewell JS, Wieck A. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol 2001;15:293-5 (Pubitemid 34024248)
119. Mendhekar DN, Andrade CR. Unilateral gynecomastia induced by risperidone in a geriatric male patient. Indian J Med Sci 2005;59:361-2 (Pubitemid 41247015)
120. Mabini R, Wergowske G, Baker FM. Galactorrhea and gynecomastia in a hypothyroid male being treated with risperidone. Psychiatr Serv 2000;51:983-5 (Pubitemid 30613003)
121. Benazzi F. Gynecomastia with risperidone-fluoxetine combination. Pharmacopsychiatry 1999;32:41 (Pubitemid 29077264)
122. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002;22:419-23 (Pubitemid 34810333)
123. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57-61 (Pubitemid 29047332)
124. Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29:125-47 (Pubitemid 36278732)
125. Lorenz RA, Weinstein B. Resolution of haloperidol-induced hyperprolactinemia with aripiprazole. J Clin Psychopharmacol 2007;27:524-5
126. Marken PA, Haykal RF, Fisher JN. Management of psychotropic- induced hyperprolactinemia. Clin Pharm 1992;11: 851-6
127. Damsa C, Bumb A, Bianchi-Demicheli F, et al. " Dopaminedependent" side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry 2004;65:1064-8
128. Boulenger A, Viseux V, Plantin-Eon I, Redon JY, Commegeille P, Plantin P. Gynaecomastia following treatment by fluoxetine. J Eur Acad Dermatol Venereol 2003;17:109
129. Sahin M, Yilmaz H, Guvener ND. A possible case of gynecomastia with fluoxetine. Ann Pharmacother 2005;39:1369
130. Llop R, Gómez-Farran F, Figueras A, Capellà D, Laporte Jr. Gynecomastia associated with enalapril and diazepam. Ann Pharmacother 1994;28:671-2
131. Jelenkovic AV, Macukanovic-Golubovic LDJ. Diazepam-associated gynecomastia. Ann Pharmacother 2005;39:201
132. Sattin RW, Roisin A, Kafrissen ME, Dugan JB, Farer LS. Epidemic of gynecomastia among illegal Haitian entrants. Public Health Rep 1984;99:504-10 (Pubitemid 14012866)
133. Brody SA, Loriaux DL. Epidemic of gynecomastia among Haitian refugees: exposure to an environmental antiandrogen. Endocr Pract 2003;9:370-5
134. Anderson ML. A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro. J Herb Pharmacother 2005;5:17-26 (Pubitemid 41536068)
135. Angwafor F, Anderson ML. An open label, dose response study to determine the effect of a dietary supplement on dihydrotestosterone, testosterone and estradiol levels in healthy males. J Int Soc Sports Nutr 2008;5:12
136. Louis MP, Heran I, Peyriere H, Blayac JP, Hillaire-Buys D. Two cases of gynaecomastia with cetirizine, a second-generation antihistamine. Therapie 2004;59:163-4 (Pubitemid 38765582)
137. Malaga I, Sanmarti FX. Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy. Epilepsia 2006;47:1576-9 (Pubitemid 44393873)
138. Zylicz Z. Painful gynecomastia: an unusual toxicity of gabapentin? J Pain Symptom Manage 2000;20:2-3 (Pubitemid 30628575)
139. Turkington RW. Serum prolactin levels in patients with gynecomastia. J Clin Endocrinol Metab 1972;34:62-6
140. Melmed S, Kleinberg D, Ho K. Pituitary physiology and diagnostic evaluation. In: Melmed S, ed. Williams textbook of endocrinology, 12th ed. Philadelphia: Elsevier Inc., 2011:179-210
141. Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc 2009;84:1010-5
142. Eckman A, Dobs A. Drug-induced gynecomastia. Expert Opin Drug Saf 2008;7:691-702
143. Johnson RE, Kermott CA, Murad MH. Gynecomastia - evaluation and current treatment options. Ther Clin Risk Manag 2011;7:145-8
144. Perdonà S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 2005;6:295-300 (Pubitemid 40590266)
145. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23:808-15 (Pubitemid 46224180)
146. Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005;8:75-83
147. Parker LN, Gray DR, Lai MK, Levin ER. Treatment of gynecomastia with tamoxifen: a double-blind crossover study. Metabolism 1986;35:705-8 (Pubitemid 16040621)
148. McDermott MT, Hofeldt FD, Kidd GS. Tamoxifen therapy for painful idiopathic gynecomastia. South Med J 1990;83: 1283-5
149. Plourde PV, Reiter EO, Jou HC, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:4428-33 (Pubitemid 39244450)
150. Wassersug RJ, Oliffe JL. The social context for psychological distress from iatrogenic gynecomastia with suggestions for its management. J Sex Med 2009;6:989- 1000